PMC:7445716 / 56226-56823 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T417","span":{"begin":30,"end":34},"obj":"Body_part"},{"id":"T418","span":{"begin":181,"end":192},"obj":"Body_part"},{"id":"T419","span":{"begin":214,"end":217},"obj":"Body_part"},{"id":"T420","span":{"begin":293,"end":300},"obj":"Body_part"},{"id":"T421","span":{"begin":313,"end":323},"obj":"Body_part"},{"id":"T422","span":{"begin":327,"end":331},"obj":"Body_part"},{"id":"T423","span":{"begin":414,"end":419},"obj":"Body_part"}],"attributes":[{"id":"A417","pred":"fma_id","subj":"T417","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A418","pred":"fma_id","subj":"T418","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A419","pred":"fma_id","subj":"T419","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A420","pred":"fma_id","subj":"T420","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A421","pred":"fma_id","subj":"T421","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A422","pred":"fma_id","subj":"T422","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A423","pred":"fma_id","subj":"T423","obj":"http://purl.org/sig/ont/fma/fma50801"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T177","span":{"begin":414,"end":419},"obj":"Body_part"}],"attributes":[{"id":"A177","pred":"uberon_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T542","span":{"begin":259,"end":279},"obj":"Disease"},{"id":"T543","span":{"begin":346,"end":354},"obj":"Disease"}],"attributes":[{"id":"A542","pred":"mondo_id","subj":"T542","obj":"http://purl.obolibrary.org/obo/MONDO_0007179"},{"id":"A543","pred":"mondo_id","subj":"T543","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T458","span":{"begin":40,"end":42},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T459","span":{"begin":55,"end":57},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T460","span":{"begin":73,"end":75},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T461","span":{"begin":88,"end":90},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T462","span":{"begin":96,"end":100},"obj":"http://purl.obolibrary.org/obo/CLO_0053704"},{"id":"T463","span":{"begin":107,"end":109},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T464","span":{"begin":123,"end":125},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T465","span":{"begin":144,"end":146},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T466","span":{"begin":160,"end":162},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T467","span":{"begin":249,"end":254},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T468","span":{"begin":313,"end":323},"obj":"http://purl.obolibrary.org/obo/CL_0000738"},{"id":"T469","span":{"begin":325,"end":331},"obj":"http://purl.obolibrary.org/obo/CLO_0001757"},{"id":"T470","span":{"begin":414,"end":419},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"T471","span":{"begin":414,"end":419},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T28596","span":{"begin":30,"end":32},"obj":"Chemical"},{"id":"T20881","span":{"begin":63,"end":65},"obj":"Chemical"},{"id":"T87785","span":{"begin":96,"end":98},"obj":"Chemical"},{"id":"T57836","span":{"begin":181,"end":192},"obj":"Chemical"},{"id":"T23927","span":{"begin":293,"end":300},"obj":"Chemical"},{"id":"T15127","span":{"begin":494,"end":513},"obj":"Chemical"},{"id":"T39282","span":{"begin":494,"end":503},"obj":"Chemical"},{"id":"T43278","span":{"begin":504,"end":513},"obj":"Chemical"},{"id":"T44421","span":{"begin":515,"end":533},"obj":"Chemical"}],"attributes":[{"id":"A16916","pred":"chebi_id","subj":"T28596","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A81289","pred":"chebi_id","subj":"T28596","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A70337","pred":"chebi_id","subj":"T20881","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A96868","pred":"chebi_id","subj":"T20881","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A49136","pred":"chebi_id","subj":"T87785","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A97665","pred":"chebi_id","subj":"T87785","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A26824","pred":"chebi_id","subj":"T57836","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A3052","pred":"chebi_id","subj":"T23927","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A42396","pred":"chebi_id","subj":"T15127","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A52553","pred":"chebi_id","subj":"T39282","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A13824","pred":"chebi_id","subj":"T43278","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A78661","pred":"chebi_id","subj":"T44421","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PubTator","denotations":[{"id":"677","span":{"begin":29,"end":33},"obj":"Gene"},{"id":"678","span":{"begin":62,"end":66},"obj":"Gene"},{"id":"679","span":{"begin":95,"end":99},"obj":"Gene"},{"id":"680","span":{"begin":130,"end":136},"obj":"Gene"},{"id":"769","span":{"begin":345,"end":355},"obj":"Species"},{"id":"842","span":{"begin":493,"end":512},"obj":"Chemical"},{"id":"925","span":{"begin":258,"end":278},"obj":"Disease"}],"attributes":[{"id":"A677","pred":"tao:has_database_id","subj":"677","obj":"Gene:3552"},{"id":"A678","pred":"tao:has_database_id","subj":"678","obj":"Gene:3569"},{"id":"A679","pred":"tao:has_database_id","subj":"679","obj":"Gene:3576"},{"id":"A680","pred":"tao:has_database_id","subj":"680","obj":"Gene:7124"},{"id":"A769","pred":"tao:has_database_id","subj":"769","obj":"Tax:2697049"},{"id":"A842","pred":"tao:has_database_id","subj":"842","obj":"MESH:C558899"},{"id":"A925","pred":"tao:has_database_id","subj":"925","obj":"MESH:D001327"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-sentences","denotations":[{"id":"T317","span":{"begin":0,"end":35},"obj":"Sentence"},{"id":"T318","span":{"begin":36,"end":68},"obj":"Sentence"},{"id":"T319","span":{"begin":69,"end":101},"obj":"Sentence"},{"id":"T320","span":{"begin":102,"end":138},"obj":"Sentence"},{"id":"T321","span":{"begin":139,"end":324},"obj":"Sentence"},{"id":"T322","span":{"begin":325,"end":597},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T697","span":{"begin":259,"end":279},"obj":"Phenotype"},{"id":"T698","span":{"begin":367,"end":380},"obj":"Phenotype"}],"attributes":[{"id":"A697","pred":"hp_id","subj":"T697","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A698","pred":"hp_id","subj":"T698","obj":"http://purl.obolibrary.org/obo/HP_0011096"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T703","span":{"begin":63,"end":67},"obj":"PR:000001393"},{"id":"T704","span":{"begin":96,"end":100},"obj":"PR:000001395"},{"id":"T705","span":{"begin":131,"end":137},"obj":"PR:000000134"},{"id":"T706","span":{"begin":181,"end":192},"obj":"CHEBI:5386;CHEBI:5386"},{"id":"T707","span":{"begin":193,"end":203},"obj":"GO:0042571"},{"id":"T708","span":{"begin":219,"end":222},"obj":"NCBITaxon:10376"},{"id":"T709","span":{"begin":259,"end":269},"obj":"UBERON:0002405"},{"id":"T710","span":{"begin":313,"end":323},"obj":"CL:0000738"},{"id":"T711","span":{"begin":346,"end":356},"obj":"SP_7"},{"id":"T712","span":{"begin":385,"end":391},"obj":"GO:0030424"},{"id":"T713","span":{"begin":474,"end":492},"obj":"CHEBI:5801;CHEBI:5801;DG_20"},{"id":"T714","span":{"begin":494,"end":503},"obj":"CHEBI:31781;CHEBI:31781;DG_23"},{"id":"T715","span":{"begin":504,"end":513},"obj":"DG_30"},{"id":"T716","span":{"begin":515,"end":533},"obj":"CHEBI:12071;CHEBI:12071;DG_36"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}

{"project":"2_test","denotations":[{"id":"32840686-32662899-63205781","span":{"begin":18,"end":20},"obj":"32662899"}],"text":"Manganotti et al. [33] RT-PCR IL-1: 0.5 pg/ml (\u003c 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8–6.4 pg/ml), IL-8: 55.0 pg/ml (6.7–16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8–12.2 pg/ml) Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disorders Normal total protein (40 mg/dl), leucocytes: 1 cell/mm3, negative SARS-CoV-2 PCR Mixed demyelinating and axonal   EMG subtype unknown Brain: no pathological findings IVIG 400 mg/kg/day (5 days) Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilation Improvement of motor symptoms"}